Altamira

Casting of Peruvian Actress Claudia Zevallos Bolsters Indie Film Tyson's Run into the Top 10 Globally on Netflix

Retrieved on: 
Tuesday, November 7, 2023
Best Actress, 59th Berlin International Film Festival, Telemundo, STARZ, Tyson's Run, RUN, Machu Picchu, Character, Altamira, LOS, El Comercio, TYSON, Latin Press, Run, The Fault in Our Stars (film), Entertainment, Film industry, Netflix

LOS ANGELES, Nov. 7, 2023 /PRNewswire/ -- The remarkable success of the heartwarming film Tyson's Run in Peru and across Latin America is a testament to the captivating journey of Claudia Zevallos, a proud Peruvian actress who is making her mark in Hollywood.

Key Points: 
  • Claudia's superb supporting role portrayal of a Peruvian Spanish teacher, Ms. Fernandez, in the film struck a chord with Latinos across the continent.
  • The success of Tyson's Run in Latin America demonstrates Claudia's dual role as a talented actress and a cultural ambassador of sorts.
  • Claudia commented, "I am truly honored to have been a part of 'Tyson's Run' and humbled by the amazing support the film and I have received.
  • Tyson's Run, TYSON'S RUN MOVIE TRAILER - YouTube , will begin streaming on Netflix in the United States on February 28th, 2024.

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

Retrieved on: 
Tuesday, September 12, 2023
KRAS, Nanoparticle, Rhinitis, Marketing, Synovitis, Heqet, Allergic rhinitis, RNA, MBA, Doctor of Philosophy, Preprint, Patent, Patient, NF-κB, MITES, AVS, DNMT3B, Rheumatoid arthritis, Joint capsule, Therapy, Myocardial infarction, Research, Small RNA, Regeneration, Sneeze, Washington University School of Law, Neoplasm, Nasal spray, FDA, Vertigo, IND, Safety, Volunteering, SAR, Altamira, Cell, IP, Immunotherapy, Messenger, NASAR, Nasal congestion, CHF, Osteoarthritis Research Society International, Rhinorrhea, Q&A, SARS-CoV-2, Infection, Clinical trial, Pollen, Inflammation, ANCOVA, OTC, Mouse, Washington University School of Medicine, Vaccine, Pharmaceutical industry, Cryptocurrency, BPPV, St. Louis

Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.

Key Points: 
  • Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m.
  • ET
    Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results.
  • Net loss for the first half of 2023 was CHF 5.4 million compared with CHF 8.2 million for the first half of 2022.
  • ET to discuss its business update and first half 2023 results.

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th

Retrieved on: 
Wednesday, September 6, 2023
Altamira, Therapy, Q&A, Cryptocurrency, Pharmaceutical industry

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced that it will host its First Half of 2023 Financial Results and Business Update Call on Tuesday, September 12, 2023.

Key Points: 
  • HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced that it will host its First Half of 2023 Financial Results and Business Update Call on Tuesday, September 12, 2023.
  • Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Retrieved on: 
Wednesday, August 23, 2023
Altamira, Therapy, Conference, Cryptocurrency

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in person on September 11-13, 2023, at Lotte New York Palace Hotel in New York City.

Key Points: 
  • HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in person on September 11-13, 2023, at Lotte New York Palace Hotel in New York City.

Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal

Retrieved on: 
Monday, July 17, 2023
Therapy, HDM, Clinical trial, Altamira, Allergic rhinitis, History, ANCOVA, PAR, Patient, Pharmaceutical industry, Medical imaging

Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of the detailed results from its clinical trial with Bentrio® nasal spray in house dust mite (“HDM”) allergic rhinitis.

Key Points: 
  • Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of the detailed results from its clinical trial with Bentrio® nasal spray in house dust mite (“HDM”) allergic rhinitis.
  • The peer-reviewed article was published in Clinical and Translational Allergy, one of the leading journals in the field of allergology.
  • The primary endpoint was the change in the Total Nasal Symptom Score (TNSS; determined in 20-minute intervals) from baseline.
  • “Also, in both studies Bentrio exhibited a lasting protective effect for several hours, reflecting its long nasal residence time.

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

Retrieved on: 
Wednesday, July 5, 2023
Heart failure, Moyamoya disease, Heart, Nanoparticle, Myocardial infarction, Therapy, Small RNA, Necrosis, American Heart Association, Head, Heqet, Altamira, RNA, Cardiac muscle, King's College London, Imperial College London, Regeneration, Ischemia, MD, Patient, School, Liver, Mortality, Science, Facial muscles, Pharmaceutical industry, Vaccine

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has entered into a collaboration and option agreement with Heqet Therapeutics s.r.l.

Key Points: 
  • Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has entered into a collaboration and option agreement with Heqet Therapeutics s.r.l.
  • Based in Turin, Italy, Heqet is a biotech spin-out from King’s College London.
  • Under the terms of the agreement, Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform and comprising certain non-coding RNAs (ncRNAs) in the regeneration of damaged heart tissue following myocardial infarction in animal models.
  • We believe that our peptide-based OligoPhore platform for RNA delivery has the potential to serve as a safe and effective vehicle for engineering controlled local cardiac regeneration.”

Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model

Retrieved on: 
Wednesday, March 22, 2023
Nanoparticle, Semaphore, Therapy, Neoplasm, Altamira, Research, Zinc finger, Domain, Cell, RNA, Immunotherapy, Washington University in St. Louis, Messenger, Sarcoma, Animal, BTB, Manuscript, Pathology, TME, Washington University School of Medicine, Tumor microenvironment, Vaccine, St. Louis

Expression of the ZBTB46 gene with SemaPhore was associated with an immunostimulatory tumor microenvironment (TME), and it was potentiated when combined with anti-PD1 immune checkpoint inhibition.

Key Points: 
  • Expression of the ZBTB46 gene with SemaPhore was associated with an immunostimulatory tumor microenvironment (TME), and it was potentiated when combined with anti-PD1 immune checkpoint inhibition.
  • In contrast, enforced ZBTB46 expression mitigated the pro-tumor TME features and restricted tumor growth, suggesting ZBTB46 as a potential target for tumor treatment.
  • In a next step, the group tested the systemic delivery of ZBTB46 mRNA with Altamira’s peptide-based SemaPhore nanoparticles in mouse models of sarcoma and metastatic breast cancer to boost ZBTB46 expression.
  • The treatment sustained ZBTB46 expression in tumor-dendritic cells and -endothelial cells and resulted in the restriction of tumor growth associated with an immunostimulatory TME.

Covalon Welcomes Martin Goldfarb, O.C., to its Board of Directors

Retrieved on: 
Thursday, March 9, 2023
Principal, TSX Venture Exchange, Learning, Marketing, Altamira, University college, Consultant, Workforce, York University, University, Sale, BC Children's Hospital Foundation, Patient, Behavior, TSX, Liberal Party of Canada candidates in the 2004 Canadian federal election, WPP, University of Toronto, Mentorship, Florida State University College of Business, Liberal Party, Management, Security (finance), Anthropology, Infor, Sociology

MISSISSAUGA, ON, March 9, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is delighted to announce that Martin Goldfarb has joined its Board of Directors.

Key Points: 
  • MISSISSAUGA, ON, March 9, 2023 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical technologies company, today is delighted to announce that Martin Goldfarb has joined its Board of Directors.
  • Brian Pedlar, Covalon's CEO, said, "I am very pleased to welcome Martin Goldfarb back on Covalon's Board.
  • Martin has been a significant, longstanding shareholder of Covalon, and I look forward to once again benefiting further from his unique insights and experiences."
  • I sincerely believe there is much more that can be achieved by Covalon for patients, healthcare providers, and shareholders alike."

Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th

Retrieved on: 
Tuesday, January 10, 2023
Altamira, Tissue, RNA transfection, Semaphore, LNP, Conference, Protein, Therapy, RNA, Research, Medicine, Liver, Cytoplasm, Medical device, Vaccine

Altamira is developing the use of mRNA to therapeutically increase the local production of specific proteins outside the liver to treat a variety of diseases.

Key Points: 
  • Altamira is developing the use of mRNA to therapeutically increase the local production of specific proteins outside the liver to treat a variety of diseases.
  • For this purpose, the Company is using its SemaPhore platform to efficiently transport those mRNA payloads into extrahepatic target cells.
  • Even the most powerful mRNA molecule is useless, however, if it cannot be delivered safely and effectively to the target tissue.
  • With our SemaPhore platform, we have the right technology to take mRNA where it is needed and release it efficiently inside target cells.”

Evantic, a Portfolio Company of Edgewater Capital Partners, Acquires Vertec Polymers, Inc.

Retrieved on: 
Tuesday, January 10, 2023
PPS, PEEK, Food, PFI, Thermal conductivity, Edgewater, Polymer, PTFE, Energy, Taft Stettinius & Hollister, PFA, Foodservice, Altamira, Thermoplastic, Evant Independent School District

HOUSTON, Jan. 10, 2023 /PRNewswire/ -- Evantic, a portfolio company of Edgewater Capital Partners, in continuing its strategy as an advanced materials engineered components platform, has acquired Vertec Polymers, Inc. ("Vertec Polymers").

Key Points: 
  • HOUSTON, Jan. 10, 2023 /PRNewswire/ -- Evantic, a portfolio company of Edgewater Capital Partners, in continuing its strategy as an advanced materials engineered components platform, has acquired Vertec Polymers, Inc. ("Vertec Polymers").
  • Vertec Polymers is a designer and manufacturer of highly engineered PEEK, PPS, PTFE, PFA, and other advanced polymeric materials through its R&D laboratory and testing facility.
  • Vertec Polymers joins Evantic's existing portfolio of innovative providers of high-performance engineered solutions, Altamira Material Solutions and Precision Fluorocarbon.
  • "Our strong materials development expertise and injection molding capabilities will complement Evantic's existing machining capabilities," stated Shawn Smith, President and CEO of Vertec Polymers.